LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Britain Courts Anthropic Amid US Defense Department Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
 - EconoTimes)
NEW ORLEANS, June 30, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (Nasdaq:AKTX), if they purchased the Company’s securities between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased securities of Akari Therapeutics and would like to discuss your legal rights and how this case might affect your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850, via email ([email protected]), or visit us at http://ksfcounsel.com/cases/akari-therapeutics-plc-nasdaqcm-aktx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 11, 2017.
About the Lawsuit
Akari Therapeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s CEO, and possibly others, caused false information about the Company to be published, including but not limited to, false information regarding the Phase 2 trial of Coversin; (ii) inadequate measures were in place to prevent such conduct; and (iii) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.
On this news, the price of Akari’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
